Olsen Harald, Andersen Anders, Nordbø Arve, Kongsgaard Ulf E, Børmer Ole P
Central Laboratory, The Norwegian Radium Hospital HF, N-0310 Oslo, Norway.
BMC Clin Pharmacol. 2004 Mar 29;4:4. doi: 10.1186/1472-6904-4-4.
Albumin is the most abundant protein in blood plasma, and due to its ligand binding properties, serves as a circulating depot for endogenous and exogenous (e.g. drugs) compounds. Hence, the unbound drug is the pharmacologically active drug. Commercial human albumin preparations are frequently used during surgery and in critically ill patients. Recent studies have indicated that the use of pharmaceutical-grade albumin is controversial in critically ill patients. In this in vitro study we investigated the drug binding properties of pharmaceutical-grade albumins (Baxter/Immuno, Octapharma, and Pharmacia & Upjohn), native human serum, and commercially available human serum albumin from Sigma Chemical Company.
The binding properties of the various albumin solutions were tested in vitro by means of ultrafiltration. Naproxen, warfarin, and digitoxin were used as ligands. HPLC was used to quantitate the total and free drug concentrations. The data were fitted to a model of two classes of binding sites for naproxen and warfarin and one class for digitoxin, using Microsoft Excel and Graphpad Prism.
The drugs were highly bound to albumin (95-99.5%). The highest affinity (lowest K1) was found with naproxen. Pharmaceutical-grade albumin solutions displayed significantly lower drug-binding capacity compared to native human serum and Sigma albumin. Thus, the free fraction was considerably higher, approximately 40 times for naproxen and 5 and 2 times for warfarin and digitoxin, respectively. The stabilizers caprylic acid and N-acetyl-DL-tryptophan used in the manufacturing procedure seem to be of importance. Adding the stabilizers to human serum and Sigma albumin reduced the binding affinity whereas charcoal treatment of the pharmaceutical-grade albumin from Octapharma almost restored the specific binding capacity.
This in vitro study demonstrates that the specific binding for warfarin and digitoxin is significantly reduced and for naproxen no longer detectable in pharmaceutical-grade albumin. It further shows that the addition of stabilizers may be of major importance for this effect.
白蛋白是血浆中含量最丰富的蛋白质,由于其配体结合特性,可作为内源性和外源性(如药物)化合物的循环储存库。因此,未结合的药物才是具有药理活性的药物。商业人白蛋白制剂常用于手术期间和重症患者。最近的研究表明,在重症患者中使用药用级白蛋白存在争议。在这项体外研究中,我们调查了药用级白蛋白(百特/免疫、奥克特珐玛和法玛西亚-普强)、天然人血清以及西格玛化学公司的市售人血清白蛋白的药物结合特性。
通过超滤在体外测试各种白蛋白溶液的结合特性。使用萘普生、华法林和地高辛作为配体。采用高效液相色谱法定量总药物浓度和游离药物浓度。使用Microsoft Excel和GraphPad Prism软件将数据拟合为萘普生和华法林两类结合位点以及地高辛一类结合位点的模型。
药物与白蛋白高度结合(95%-99.5%)。萘普生的亲和力最高(最低K1)。与天然人血清和西格玛白蛋白相比,药用级白蛋白溶液的药物结合能力显著降低。因此,游离部分明显更高,萘普生约高40倍,华法林和地高辛分别高5倍和2倍。生产过程中使用的稳定剂辛酸和N-乙酰-DL-色氨酸似乎很重要。向人血清和西格玛白蛋白中添加稳定剂会降低结合亲和力,而对奥克特珐玛的药用级白蛋白进行活性炭处理几乎可恢复其特异性结合能力。
这项体外研究表明,药用级白蛋白对华法林和地高辛的特异性结合显著降低,对萘普生则不再能检测到特异性结合。研究还进一步表明,添加稳定剂可能对此效应起主要作用。